These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17435848)

  • 1. [HIV lipodystrophy syndrome: a new challenge to the endocrinologist].
    Valente O; Valente AM
    Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):3-4. PubMed ID: 17435848
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
    Introcaso CE; Hines JM; Kovarik CL
    J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-associated lipodystrophy syndrome: LioN-HAART cohort: (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy.
    Lauenroth-Mai E; Schlote F
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):253-5. PubMed ID: 12394807
    [No Abstract]   [Full Text] [Related]  

  • 4. ART regimes and fat: the healing hand wielding the sword.
    Domingo P; Espinet J; Vidal F
    Lancet HIV; 2017 Jan; 4(1):e2-e3. PubMed ID: 27815067
    [No Abstract]   [Full Text] [Related]  

  • 5. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 6. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 7. [Metabolic changes in HIV infected patient].
    Castelo Filho A; Abrão P
    Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):5-7. PubMed ID: 17435849
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV and increased risk of cardiovascular diseases.
    Das S
    Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does atazanavir cause lipodystrophy?
    Gazzard BG; Moyle G
    J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting to the HAART of insulin resistance.
    Nolan D; Mallal S
    AIDS; 2001 Oct; 15(15):2037-41. PubMed ID: 11600834
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment options for lipodystrophy in HIV-positive patients.
    Behrens GM
    Expert Opin Pharmacother; 2008 Jan; 9(1):39-52. PubMed ID: 18076337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipodystrophic syndromes in HIV-infected patients receiving antiretroviral treatment].
    Simeoni J
    Ann Endocrinol (Paris); 2003 Dec; 64(6):490-1. PubMed ID: 15080164
    [No Abstract]   [Full Text] [Related]  

  • 16. Key reports from the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV 2007.
    Nestorowicz A; Cameron S
    Antivir Ther; 2007; 12(6):987-98. PubMed ID: 17926655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic complications of HIV therapy in children.
    McComsey GA; Leonard E
    AIDS; 2004 Sep; 18(13):1753-68. PubMed ID: 15316336
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
    Pérez-Molina JA; Domingo P; Martínez E; Moreno S
    J Antimicrob Chemother; 2008 Aug; 62(2):234-45. PubMed ID: 18480167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.
    Mallewa JE; Wilkins E; Vilar J; Mallewa M; Doran D; Back D; Pirmohamed M
    J Antimicrob Chemother; 2008 Oct; 62(4):648-60. PubMed ID: 18565973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.
    García-Benayas T; Blanco F; de la Cruz JJ; Soriano V; González-Lahoz J
    AIDS; 2003 Apr; 17(6):921-4. PubMed ID: 12660543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.